Omacor (Omega-3-Acid Ethyl Esters 90)

Omega-3-acid ethyl esters, the active ingredient in Omacor, is a prescription omega‑3 fatty acid presented as a 90% ethyl ester concentrate for oral use. It is indicated for lipid‑lowering therapy in adults with severe hypertriglyceridaemia, particularly when diet alone is insufficient. GNH USA supplies Omacor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omacor is a prescription omega‑3 fatty acid that lowers elevated triglyceride levels through modulation of lipid metabolism: - Severe hypertriglyceridaemia: reduces triglycerides and helps meet target levels. - Familial hypercholesterolemia (adjunctive therapy): supports overall lipid profile improvement. - Mixed dyslipidaemia: contributes to lowering triglyceride concentrations alongside other lipid‑lowering agents.

Adverse reactions to Omacor are generally dose‑related and may vary in frequency.

Common Side Effects: - Fish‑like aftertaste. - Mild gastrointestinal discomfort (nausea, dyspepsia, abdominal pain). - Diarrhoea. - Flatulence. - Headache.

Serious or Rare Side Effects: - Acute pancreatitis. - Severe allergic reactions (anaphylaxis, angio‑edema). - Elevated liver enzymes. - Bleeding complications, especially when combined with anticoagulants. - Hyperglycaemia in susceptible individuals.

When prescribing Omacor, clinicians should consider several safety aspects: - Monitor triglyceride levels: regular laboratory testing is recommended to assess therapeutic response. - Assess bleeding risk: evaluate concomitant use of anticoagulants or antiplatelet agents. - Review hepatic function: baseline liver enzymes should be obtained before initiating therapy. - Pregnancy and lactation: use only if the potential benefit outweigh   - Store at below 25°C: keep in the original packaging, protect  

A